Top > Search of International Patents > COMPOSITION FOR INCREASING BONE MASS

COMPOSITION FOR INCREASING BONE MASS

Foreign code F130007669
File No. S2012-0461-N0
Posted date Oct 17, 2013
Country WIPO
International application number 2013JP055555
International publication number WO 2013129620
Date of international filing Feb 28, 2013
Date of international publication Sep 6, 2013
Priority data
  • P2012-042160 (Feb 28, 2012) JP
Title COMPOSITION FOR INCREASING BONE MASS
Abstract It has been discovered that semaphorin 3A (Sema3A), which is expressed by osteoblastic cells, exhibits a strong bone-protecting action by simultaneously inhibiting bone resorption and promoting bone formation. It has also been found that systemic administration of Sema3A (by intravenous injection) or local administration thereof to a bone damage site makes it possible to increase bone mass of the administration target.
Outline of related art and contending technology BACKGROUND ART
With the aging society, fracture, osteoporosis, rheumatoid arthritis, back pain such as pain increased bone disease patient. In bone tissue, osteoblasts responsible for bone formation, and osteoclasts responsible for bone resorption works in concert, a balanced bone resorption and bone formation by bone resorption, bone homeostasis, and thus the function of the bone tissue is maintained. Is in bone homeostasis, via Calcium is maintained primarily by the endocrine system and is considered over the years, the immune system and nervous system involved in the control factor is maintained by, being to recently been found (non-patent document 1-2). In addition, the bone homeostasis, as well as loss of ovarian function due to aging deforms due to such factors, such as a decrease in bone formation, and abnormal bone resorption or enhance, and a decrease in bone mass (bone density), various bone diseases occur (non-patent document 3-4). Such bone diseases, fractures, bone defects, osteoporosis, Osteomalacia, osteopenia, waist back pain, bone Paget's disease, ankylosing spondylitis, rheumatoid arthritis, osteoarthritis, metastatic bone tumor initial /, periodontal disease, periodontitis and the like implant known. And in particular elderly people suffering from bone disease, the required level of motion in the daily life become difficult even, in some cases, also the danger of the stay. Therefore, the aging proceeds in modern society, preventing bone diseases, is an important significance for the treatment.
The current, as a therapeutic agent for bone disease, active vitamin D3 agent, a bisphosphonate agent, calcitonin formulations, containing estradiol hormone preparations, vitamin K2 agent, such as parathyroid hormone (PTH) is generally used in the formulation. In addition, have fewer side effects, more effective as therapeutic agents, estradiol derivatives, active vitamin D3 derivatives, which have been developed bisphosphonate derivative (patent document 1).
However, the blood calcium concentration of vitamin D3 and has an effect on increasing, bisphosphonates for bone resorption inhibition of estradiol and has the effect that, both directly promote osteogenesis by osteoblasts effect may not. On the other hand, but PTH promotes bone formation, bone resorption do not significantly affect the for. In addition, bone resorption and bone formation and bone resorption (coupling factor) via a coupling factor for cooperating with the (non-patent document 5-6), a bisphosphonate anti-bone resorption agent such as estradiol and used for a long time, suppress the formation of an appropriate bone ulha and, low-quality bone as a result of the accumulation of the (non-patent document 6-9).
Therefore, truly effective bone disease, as well as the development of methods of therapeutic agent in order to enable, a mechanism to maintain homeostasis of the bone to elucidate in detail, while suppressing bone resorption, promoting bone formation to identify molecules that can has been urgently required. However, identification of such molecules has not been conducted, bone resorption and bone formation and bone resorption can be controlled is tuned to the prevention of bone diseases, such as the provision of the therapeutic agent yet developed.
On the other hand, axonal guidance molecule, and widely expressed outside the nervous system, where the cell migration, immune response, such as angiogenesis development and tissue revealed that the control (non-patent document 10-11) being. In addition, from recent research results, including the skeletal system, in various biological systems, axonal guidance molecule responsible for an important role has been suggested (non-patent document 12-14). Axonal guidance molecule 1 (Sema3A) is a type of the semaphorin 3A protein, and secreted proteins, membrane proteins (Neuropilin 1) and Nrp1 (Plexin A1) Plexin-A1 and form a complex, various signals that are known. Is in the nervous system, nerve axons of neuronal guidance factor determines a directivity function as has been made clear (non-patent document 15-16), in addition, in the immune system, such as factor inhibit the migration of dendritic cells, as a factor of suppressing the activation of T cells, also known function as a Sema3A (patent document 2). Further, with respect to the bone, in Sema3A knockout mice, an abnormality of the bone and cartilage formation and has been observed (non-patent document 17). In addition, the expression of Sema3A mRNA whereas osteoblasts, osteoclasts do not been confirmed (non-patent document 18). However, Sema3A protein, in osteoblasts and osteoclasts, which exert their effect whether has not been clarified.
Scope of claims (In Japanese)請求の範囲 [請求項1]
 セマフォリン3Aを有効成分として含有する、骨量を増加させるための組成物。

[請求項2]
 セマフォリン3Aを有効成分として含有する、骨量の低減を伴う疾患を治療又は予防するための組成物。

[請求項3]
 セマフォリン3Aを対象に投与し、対象の骨量を増加させるための方法。

[請求項4]
 セマフォリン3Aを対象に投与し、対象の骨量の低減を伴う疾患を治療又は予防するための方法。

[請求項5]
 骨量を増加させる活性を有する化合物をスクリーニングする方法であって、
(a)Nrp1タンパク質に試験化合物を接触させる工程、
(b)Nrp1タンパク質に結合する活性を有する化合物を選択する工程、
を含む方法。

[請求項6]
 骨量を増加させる活性を有する化合物をスクリーニングする方法であって、さらに
(c)前記工程(b)において選択された化合物を、破骨細胞分化系に接触させ、破骨細胞分化を検出し、該分化を抑制する化合物を選択する工程、及び/又は、
(d)前記工程(b)において選択された化合物を、骨芽細胞分化系に接触させ、骨芽細胞分化又は脂肪細胞分化を検出し、骨芽細胞分化を促進する化合物又は脂肪細胞分化を抑制する化合物を選択する工程
を含む、請求項5に記載の方法。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
  • Inventor
  • TAKAYANAGI Hiroshi
  • NAKASHIMA Tomoki
  • HAYASHI Mikihito
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close